Loading…
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-80M | $-74M | $-69M | -45.9% | - | - |
| 2024 | $0M | $-70M | $-68M | $-57M | -56.6% | - | - |
| 2023 | $0M | $-56M | $-52M | $-45M | -44.6% | - | - |
| 2022 | $0M | $-39M | $-41M | $-40M | -27.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 41.61 | 55.99 | 70.42 | 79.89 |
| Operating Income | -41.61 | -55.99 | -70.42 | -79.89 |
| EBITDA | -39.24 | -55.96 | -70.39 | -79.86 |
| EBIT | -39.25 | -55.99 | -70.42 | -79.89 |
| Pretax Income | -41.06 | -51.79 | -68.46 | -74.41 |
| Net Income | -41.06 | -51.79 | -68.46 | -74.41 |
| Net Income Common Stockholders | -41.06 | -51.79 | -68.46 | -74.41 |
| Total Expenses | 41.61 | 55.99 | 70.42 | 79.89 |
| Interest Expense | 1.81 | 0 | 0 | 0 |
| Interest Income | 0.08 | 4.21 | 4.87 | 5.48 |
| Research And Development | 32.49 | 43.81 | 55.74 | 61.53 |
| Selling General And Administration | 9.36 | 12.18 | 14.68 | 18.37 |
| Normalized EBITDA | -41.52 | -55.95 | -67.48 | -79.86 |
| Normalized Income | -43.34 | -51.78 | -65.55 | -74.41 |
| Basic EPS | -2.26 | -1.01 | -1.33 | -0.98 |
| Diluted EPS | -2.32 | -1.01 | -1.33 | -0.98 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 2.28 | -0.01 | -2.91 | 0 |
| Total Unusual Items Excluding Goodwill | 2.28 | -0.01 | -2.91 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -41.06 | -51.79 | -68.46 | -74.41 |
| Reconciled Depreciation | 0.01 | 0.03 | 0.04 | 0.03 |
| Net Interest Income | -1.73 | 4.21 | 4.87 | 5.48 |
| Net Income From Continuing And Discontinued Operation | -41.06 | -51.79 | -68.46 | -74.41 |
| Total Operating Income As Reported | -41.84 | -55.99 | -70.42 | -79.89 |
| Diluted Average Shares | 19.49 | 51.19 | 51.47 | 76 |
| Basic Average Shares | 18.20 | 51.19 | 51.47 | 76 |
| Diluted NI Availto Com Stockholders | -45.13 | -51.79 | -68.46 | -74.41 |
| Average Dilution Earnings | -4.07 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -41.06 | -51.79 | -68.46 | -74.41 |
| Net Income Continuous Operations | -41.06 | -51.79 | -68.46 | -74.41 |
| Other Income Expense | 2.28 | -0.01 | -2.91 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 0 |
| Special Income Charges | -1.77 | 0 | 0 | 0 |
| Other Special Charges | 1.77 | 0 | 0 | 0 |
| Gain On Sale Of Security | 4.05 | -0.01 | -2.91 | 0 |
| Net Non Operating Interest Income Expense | -1.73 | 4.21 | 4.87 | 5.48 |
| Interest Expense Non Operating | 1.81 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.08 | 4.21 | 4.87 | 5.48 |
| Other Operating Expenses | -0.23 | 0 | 0 | 0 |
| General And Administrative Expense | 9.36 | 12.18 | 14.68 | 18.37 |
| Other Gand A | 9.36 | 12.18 | 14.68 | 18.37 |
| Salaries And Wages | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Rezolute, Inc.this co. | RZLT | $299M | - | 2.53 | -45.9% | -1.89 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Greenwich LifeSciences, Inc. | GLSI | $299M | - |
| 136.71 |
| -623.1% |
| -15.09 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| Peer Median | - | 15.33 | 1.81 | -41.3% | -1.40 | |